BioSpace News Archive

Asklepios BioPharmaceutical, Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, presented first-in-human data from a Phase 1 trial investigating AB-1002 for the treatment of patients with congestive heart failure at this year’s American Heart Association Scientific Sessions, which are being held in Philadelphia, U.S., from November 11 to 13, 2023.3,4

Lexicon Pharmaceuticals, Inc. announced that a post hoc analysis of clinical data from the SCORED trial demonstrated that clinical benefit from INPEFA® use in heart failure and major adverse cardiovascular events related outcomes was observed as early as approximately three months in patients at high risk for cardiovascular events.

BridgeBio Pharma, Inc. presented additional Phase 3 data from ATTRibute-CM, its study of acoramidis in transthyretin amyloid cardiomyopathy, or ATTR-CM, at the American Heart Association Scientific Sessions 2023.

Ascletis Pharma Inc. announces late-breaking abstract poster presentation of interim results from Phase IIb expansion cohort of ASC22 for functional cure of chronic hepatitis B, and abstract poster presentation of Phase I study results of ASC41 for treatment of non-alcoholic steatohepatitis at The Liver Meeting® 2023 of the American Association for the Study of Liver Diseases.

Anthos Therapeutics, Inc., a clinical stage company developing innovative therapies for cardiovascular diseases, founded by Blackstone Life Sciences, announced during a Late-Breaking session of the American Heart Association meeting that abelacimab demonstrated a highly significant reduction in bleeding events across all primary and secondary endpoints versus a standard of care direct-oral anticoagulant.

Amarin Corporation plc announced results from new REDUCE-IT analyses showing that among statin-treated patients in a prespecified subgroup with history of Metabolic Syndrome, but without diabetes at baseline, the addition of VASCEPA/VAZKEPA significantly reduced the risk of first and total cardiovascular events.

89bio, Inc. announced additional data from a post-hoc analysis of the ENLIVEN Phase 2b trial evaluating treatment with pegozafermin in a subgroup of patients with F4 NASH.

A recent study from Hospital for Special Surgery and others has found a correlation between obesity and more severe disease flare symptoms that negatively affect quality of life in patients with early rheumatoid arthritis, a systemic, autoimmune, inflammatory disorder affecting multiple joints in the body.

Telix Pharmaceuticals Limited announces that the first patient has been dosed in the Company’s Phase III ProstACT GLOBAL study of its investigational prostate-specific membrane antigen targeting radio-antibody drug conjugate therapy, TLX591.